Report Overview

The EU Allergy Treatment market size stood at around USD 544 million in 2019 and is projected to reach USD xx million by 2028, exhibiting a CAGR of xx% during the forecast period

Allergy is a condition in which the immune system reacts abnormally to a foreign substance. An allergy is an immune system reaction to something that is normally harmless. Europe accounted for the largest share of 69.1% in 2019 globally. This can be attributed to strong presence of leading market players, such as ASIT Biotech, Circassia, Mylan N.V., and Merck KGaA

An estimated 17 million Europeans have food allergies, and according to the European Academy of Allergy and Clinical Immunology (EAACI), over the past decade, hospital admissions for severe allergic reactions in children have risen seven-fold. Therefore, with the growing incidences of allergic diseases, the treatment market for the same is expected to grow at a significant pace



Market Drivers

Increasing number of cases of allergic diseases like hay fever and anaphylaxis, increasing demand for non-prescribed OTC (over-the-counter) drugs for allergy treatment, and rapid growth of self-medication among consumers are major factors driving the growth of the market. Rising investment patterns in allergy drug development by the manufacturers and research and development of novel allergy immunotherapy (AIT) is expected to further enhance the overall Allergy Treatment Market demand during the forecast period